Trials / Completed
CompletedNCT00213083
Efficacy Study of the Vaginal Gel Carraguard to Prevent HIV Transmission
Phase 3 Study of the Efficacy and Safety of the Microbicide Carraguard® in Preventing HIV Seroconversion in Women
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 6,203 (actual)
- Sponsor
- Population Council · Academic / Other
- Sex
- Female
- Age
- 16 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
The purposes of this study are to determine whether Carraguard® Gel can prevent the transmission of HIV when used during vaginal intercourse, and to confirm that the gel is safe for vaginal use.
Detailed description
This study is designed to show if Carraguard® can protect women against HIV if it is used before sex, and is safe for long-term use.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Carraguard (PC-515) |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2007-04-01
- Completion
- 2007-04-01
- First posted
- 2005-09-21
- Last updated
- 2017-08-15
Locations
3 sites across 1 country: South Africa
Source: ClinicalTrials.gov record NCT00213083. Inclusion in this directory is not an endorsement.